New Stock News | Yimufeng Biotechnology's Hong Kong IPO prospectus has expired.
Shenzhen Yimufeng Biotechnology Co., Ltd. (abbreviated as Yimufeng Biotechnology) submitted its Hong Kong stock prospectus on February 13, 2026, which will expire six months later on August 13, 2026.
Shenzhen Yimu Feng Biotechnology Co., Ltd. (abbreviated as Yimu Feng Biotechnology) submitted its Hong Kong IPO prospectus on February 13, 2026, which will expire six months later on August 13, 2026. Huatai International is the exclusive sponsor for the submission.
According to the previously disclosed prospectus, Yimu Feng Biotechnology is a globally leading innovative cell therapy company. The company's core product (IMC002) is a potential best-in-class anti-CLDN18.2 CAR-T cell therapy candidate, which is the second most advanced solid tumor CAR-T cell therapy candidate globally and is currently in the critical clinical (Phase III) trial stage.
Related Articles
Palo Alto Networks (PANW.US) is actively seeking acquisition opportunities and has attempted to acquire Datadog (DDOG.US) and Okta (OKTA.US).
US Stock Market Move | Kanzhun Ltd. Sponsored ADR (BZ.US) surged over 18% with Q2 revenue increasing by 14.1% year-on-year.
US Stock Market Move | The MSCI index exclusion risk strikes again, and Strategy (MSTR.US) has dropped over 4%.
Palo Alto Networks (PANW.US) is actively seeking acquisition opportunities and has attempted to acquire Datadog (DDOG.US) and Okta (OKTA.US).
US Stock Market Move | Kanzhun Ltd. Sponsored ADR (BZ.US) surged over 18% with Q2 revenue increasing by 14.1% year-on-year.
US Stock Market Move | The MSCI index exclusion risk strikes again, and Strategy (MSTR.US) has dropped over 4%.
RECOMMEND
